Segall Bryant & Hamill LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Segall Bryant & Hamill LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,670 shares of the company’s stock after acquiring an additional 367 shares during the period. Segall Bryant & Hamill LLC’s holdings in Johnson & Johnson were worth $5,303,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. CoreFirst Bank & Trust purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $2,323,000. Grantvest Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $439,000. Lynx Investment Advisory boosted its holdings in Johnson & Johnson by 12.3% in the fourth quarter. Lynx Investment Advisory now owns 2,088 shares of the company’s stock valued at $302,000 after purchasing an additional 229 shares during the period. ICW Investment Advisors LLC grew its stake in Johnson & Johnson by 7.8% during the 4th quarter. ICW Investment Advisors LLC now owns 16,568 shares of the company’s stock worth $2,396,000 after purchasing an additional 1,193 shares in the last quarter. Finally, TAGStone Capital Inc. increased its holdings in Johnson & Johnson by 1.7% during the 4th quarter. TAGStone Capital Inc. now owns 22,742 shares of the company’s stock worth $3,289,000 after purchasing an additional 391 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.9 %

Shares of NYSE:JNJ opened at $163.22 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $393.33 billion, a P/E ratio of 24.54, a P/E/G ratio of 2.56 and a beta of 0.47. The firm has a fifty day moving average price of $158.35 and a 200 day moving average price of $156.23.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.29 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Stifel Nicolaus lowered their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Wells Fargo & Company lowered their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.